• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·VIJAYA.NS
Share

Vijaya Diagnostic Centre Limited Stocks

₹ 1279.2Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.40B

₹ 1279.2
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vijaya Diagnostic Centre Limited delivers a broad spectrum of diagnostic services to patients across India. Its extensive laboratory offerings include clinical biochemistry, haematology (and immune-haematology), clinical pathology, histopathology, cytopathology, microbiology, serology, cytogenetics, and molecular pathology. For imaging, the company provides advanced radiology services such as magnetic resonance imaging (MRI), multi-slice CT, 3D dental CBCT, mammography, DEXA/bone densitometry, ultrasound with color doppler, nuclear medicine including PET/CT, and digital X-rays. Beyond these, specialized services cover cardiology, neurology, and gastroenterology. The center also offers health check-up packages and convenient home sample collection. Headquartered in Hyderabad, India, and founded in 1981, Vijaya Diagnostic Centre operates a significant network of 80 diagnostic centers and 11 reference laboratories. These facilities are spread across 13 cities and towns, primarily in Telangana and Andhra Pradesh, alongside the National Capital Region and Kolkata.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of VIJAYA.NS is 1387 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026